$-2.16
(Market cap
$281 Mln
Revenue (TTM)
$103 Mln
P/E Ratio
--
P/B Ratio
27.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-5.4 %
-
ROCE
-- %
-
Industry P/E
33.74
-
EV/EBITDA
-2.7
-
Debt to Equity
5.1
-
Book Value
$--
-
EPS
$-3.2
-
Face value
--
-
Shares outstanding
10,551,118
6 Years Aggregate
CFO
$-156.83 Mln
EBITDA
$-186.88 Mln
Net Profit
$-271.01 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Biodesix Inc (BDSX)
| 318.2 | 29.3 | 92.0 | 205.8 | -5.0 | -30.5 | -- |
|
BSE Sensex
| -9.1 | 1.1 | 1.2 | -4.8 | 5.8 | 6.6 | 10.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Biodesix Inc (BDSX)
| -77.8 | -16.7 | -20.0 | -56.5 | -73.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Biodesix Inc (BDSX)
|
28.4 | 281.0 | 102.9 | -27.8 | -19.3 | -- | -- | 27.7 |
| 523.1 | 7,065.2 | 2,595.0 | 275.0 | 14.1 | 30.4 | 26.9 | 8.4 | |
| 119.9 | 11,869.0 | 6,206.1 | 621.0 | 18.6 | 16.2 | 20.2 | 4.6 | |
| 31.7 | 7,433.4 | 2,578.1 | -142.0 | -6.3 | -32.8 | -- | 22.4 | |
| 12.3 | 4,764.2 | 1,584.8 | 50.6 | 4.9 | 3.4 | 95.9 | 3.3 | |
| 24.0 | 3,549.9 | 5,693.5 | 209.6 | 6.0 | 16.2 | 18 | 2.8 | |
| 50.1 | 4,147.5 | 1,003.0 | -24.3 | 5.5 | -2.1 | 294.5 | 1.5 | |
| 75.4 | 6,045.6 | 2,268.9 | -21.1 | 4.7 | -4.5 | -- | 5.5 | |
| 19.5 | 5,584.8 | 1,216.2 | 163.5 | 33.5 | 25.7 | 33.7 | 8.2 | |
| 173.5 | 10,460.5 | 5,486.7 | 378.7 | 9.2 | 16.2 | 28.2 | 4.3 |
Shareholding Pattern
View DetailsAbout Biodesix Inc (BDSX)
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in... identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado. Read more
-
President, CEO & Director
Mr. Scott Hutton
-
President, CEO & Director
Mr. Scott Hutton
-
Headquarters
Louisville, CO
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Biodesix Inc (BDSX)
What is the current share price of Biodesix Inc (BDSX) Today?
The share price of Biodesix Inc (BDSX) is $28.44 (NASDAQ) as of 27-Aug-2026 16:00 EDT. Biodesix Inc (BDSX) has given a return of -5.03% in the last 3 years.
What is the current PB & PE ratio of Biodesix Inc (BDSX)?
Since, TTM earnings of Biodesix Inc (BDSX) is negative, P/E ratio is not available.
The P/B ratio of Biodesix Inc (BDSX) is 27.73 times as on 21-Aug-2026, a 683 premium to its peers’ median range of 3.54 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.56 |
-22.25 |
2024 |
-0.26 |
0.54 |
2023 |
-0.16 |
1.85 |
2022 |
-0.10 |
0.32 |
2021 |
-0.17 |
0.36 |
What is the 52 Week High and Low of Biodesix Inc (BDSX)?
The 52-week high and low of Biodesix Inc (BDSX) are Rs 31.31 and Rs 5.26 as of 28-Aug-2026.
What is the market cap of Biodesix Inc (BDSX)?
Biodesix Inc (BDSX) has a market capitalisation of $ 281 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Biodesix Inc (BDSX)?
Before investing in Biodesix Inc (BDSX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.